The Latest Cardiac and Vascular News
THE WOODLANDS, Texas, May 31, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of sotagliflozin […]
Post hoc analysis of pooled clinical data from the SOLOIST and SCORED trials supporting benefit of sotagliflozin presented at the virtual American Heart Association Scientific Sessions 2021, including: Sotaglifozin significantly reduced total cardiovascular deaths, hospitalizations for heart failure, and urgent […]
Rapid benefit of sotagliflozin supported by data from the SOLOIST and SCORED trials presented at ESC Congress 2021 – The Digital Experience, including: 33% absolute risk reduction in the composite cardiovascular endpoint in type 2 diabetes patients with acute decompensated […]
